February 09, 2010
Company News: AstraZeneca
The FDA approved Crestor for use in patients who are not currently suffering from heart disease but who may be considered at-risk based on age (50 and over for men, 60 and over for women), elevated CRP levels and at least one other risk factor, including smoking, hypertension, low HDL-C or family history of early heart disease. In observance of the PhRMA guiding principles on DTC, the brand will defer consumer advertising on the expanded label for awhile while reps detail doctors on it first. Messaging around the brand's unique indication for slowing the progression of atherosclerosis will continue to be a key part of the brand's overall message, said an AstraZeneca spoke.